Hello and welcome to the Annual Meeting of Shareholders of UroGen Pharma Ltd. At the end of the meeting, we'll have a question and answer session. You can submit questions at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Liza Barrett, member of the Board of Directors, as well as President and Chief Executive Officer of UroGen Pharma Ltd. Thank you. Good morning and welcome to the 2025 Annual Meeting of Shareholders of UroGen Pharma. My name is Liz Barrett, President, CEO, member of the Board of Directors of UroGen Pharma. I am proud to share a transformative milestone for UroGen: the FDA approval and launch of ZUSDURI, the first and only non-surgical intravesical therapy for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer. This approval, backed by strong clinical data, positions ZUSDURI as a potential new standard of care and a cornerstone of our commercial business, unlocking an estimated U.S. market opportunity exceeding $5 billion. It marks our evolution into a multi-product company, expanding our reach to a broader patient population, strengthening our commercial foundation, and positioning us to drive sustainable growth and long-term shareholder value. Joining me today from my management team are Chris Degnan, Chief Financial Officer; Jason Smith, General Counsel, Chief Compliance Officer and Secretary; and Mark Schoenberg, Chief Medical Officer. I would also like to introduce Michael Bay of PricewaterhouseCoopers LLP, representing the company's independent registered public accounting firm; and Asa Henin from Cooley LLP; and Ari Fried from Gornitzky & Company, the company's outside legal counsel, who are also in attendance virtually. Tim Wu, our controller, will act as the inspector of elections for today's meeting. The meeting will now be officially called to order. The time is 10:02 A.M., and the polls are open for voting on all matters to be presented. As you know, we are hosting today's meeting through a virtual online platform. We will proceed with the formal business of the meeting as set forth in the notice of annual meeting and proxy statement. We will first present the six proposals submitted by our Board for approval at today's meeting. After we present the proposals, Chris will review any questions and read those that are germane to this meeting out loud before the company responds. Shareholders of record and registered beneficial owners may submit questions or comments for the Q&A portion of the meeting. To ask a question, click on the "Message" icon on your screen to submit your question or comment online. Please submit your questions now to make sure they are received in a timely fashion for our review and response. Please note the rules of conduct for today's meeting were posted in the annual proxy statement materials and are available as part of the virtual meeting. We invite shareholders with questions not germane to the proposals to contact our investor relations department. Please see the Media and Investors tab of our website. We will announce the preliminary results of the voting after all the proposals have been presented. As I mentioned earlier, the polls are open for voting on all matters to be presented. Each ordinary share is entitled to one vote. After I describe each item to be voted on, we will close the polls. We will not accept ballots, proxies, revocations, or changes after the closing of the polls. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now, and your shares will be voted as previously instructed. If you intend to vote and have not already done so, you must submit your vote online now for your vote to be counted. If you have not voted, I encourage you to vote online now. At this time, Chris, please report with respect to the mailing of the notice of the meeting and the shareholders' list. I have at this meeting a complete list of the holders of record of the company's ordinary shares on July 14th, 2025, the record date for this meeting. The list of shareholders of record is available from the inspector of elections for inspection by shareholders of record during this meeting for any shareholder wishing to see it. I also have an affidavit certifying that commencing on July 15th, 2025, the materials for this Annual Meeting of Shareholders were mailed to all shareholders of record at the close of business on July 14th, 2025. We will now proceed with the formal business of this meeting. There are six proposals to be considered by the shareholders of this meeting. The first item of business today is the election of the seven directors to serve until the Annual Meeting of Shareholders in 2026 and until their successors are elected. The nominees for directors are Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Jr., Leana Wen, and Daniel Wildman. The second item of business today is to approve amendments to the company's 2024 Non-Employee Director and Officer Compensation policy. The third item of business today is the approval of an amendment to the company's 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 2.75 million shares. The fourth item of business today is the advisory vote to approve the compensation of the company's named executive officers, as disclosed in the proxy statement for the annual meeting. The fifth item of business today is the advisory vote on the preferred frequency of shareholder advisory vote on the compensation of the company's named executive officers. The sixth item of business today is the approval of the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the company's auditor until our 2026 Annual Meeting of Shareholders. This was the final proposal for today's meeting. Do we have any questions at this time that are germane to any of these proposals? Our records show that no questions have been submitted. Since there are no questions that are germane to the proposals at today's meeting, we will now close the polls. The time is now 10:07 A.M., and the polls are now closed for voting. May we have the results of the voting? I've been informed by the Inspector of Elections that proxies have been received for 33,179,064 of the 46,201,334 ordinary shares outstanding on the record date, which represents approximately 71.8% of the total number of shares outstanding on the record date. The preliminary report of the Inspector of Elections covering the proposals presented at this meeting indicates that all six proposals are carried. Please note that these results are preliminary, and we expect to receive the final tally within the next two business days. As such, we anticipate reporting our final voting results on Form 8-K to be filed with the SEC within four business days after the end of this meeting. This concludes the 2025 Annual Meeting of Shareholders for UroGen Pharma. Thank you again for your attendance at today's meeting and for your continued support. The meeting is now adjourned, and you may now disconnect. Again, thank you all for joining. Meeting has been concluded. You can disconnect.